XF-73 is the lead compound in Destiny’s pipeline - followed by other compounds in earlier stages of development. Currently in clinical development for nasal decolonisation of Staphylococcus aureus, including MRSA, XF-73 is also under development for other indications.

Infection control protocols now emphasise not only the need to screen patients entering hospital, but to effectively decolonise nasal carriage of Staphylococcus aureus:

"Patients receiving prophylaxis for an operative procedure and in an outbreak situation under the advice of the infection control team should undergo nasal decolonization." Coia JE, JHI 2006

Acting as a reservoir, nasal carriage of Staphylococcus aureus poses a significant health risk. Unfortunately, it is becoming resistant to existing topical antibiotics used in nasal decolonisation, severely compromising their effectiveness and leaving thousands of patients open to the risk of infection, especially MRSA.

XF-73 has been extensively studied in vitro and shows great potential. Notably, it shows:

• Rapid bactericidal activity
• No emergence of resistance in stringent multi-passage testing
• Broad spectrum of activity against Gram-positive bacteria, including multiple strains of MRSA

XF-73 is now in clinical development for nasal decolonisation of Staphylococcus aureus and is under further development for additional topical indications.

Destiny will select appropriate global partners to commercialise this exciting product. For further information please contact us
at busdev@destinypharma.com.